Enhance your understanding of optimal treatment approaches for HER2+ early breast cancer with these prIME Oncology downloadable slides. A variety of therapeutic strategies are covered, including short duration regimens, extended adjuvant therapy, dual HER2 blockade, and patient selection for these strategies. Optimizing the risk-benefit profile of different regimens is also addressed, with information on prevention and management of adverse events. Finally, emerging agents and potential future opportunities provided by new HER2-targeted strategies that address areas of continuing unmet clinical need are covered.
Sep 13, 2017
Sep 13, 2018
- Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Centre for Haematology and Oncology Bethanien, Frankfurt, Germany
The case for dual blockade
- Michael Untch, MD, PhD, HELIOS Klinikum Berlin-Buch, Berlin, Germany
The case for extended adjuvant treatment
- Thomas Bachelot, MD, PhD, Centre Léon Bérard, Lyon, France
The case for reduced treatment
- Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany
Optimizing the risks and benefits of treatment
- Suzette Delaloge, MD, MSc, Gustave Roussy, Villejuif, France
Borrowing from Maria to treat Sophia: A risk-adapted approach to treatment
- Cristina Saura, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain
Emerging treatments for HER2+ and mutant breast cancer
- Hope S. Rugo, MD, FASCO, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
This educational activity is specifically designed to meet the needs of oncologists, registered nurses, and other healthcare professionals involved in the treatment of patients with CINV.
After successful completion of this educational activity, participants should be able to:
- Evaluate the results of recent clinical trials in HER2+ early breast cancer that explore the evolution of adjuvant treatment strategies
- Select the optimum HER2-targeted strategy and duration of treatment to improve long-term disease endpoints in patients with HER2+ early breast cancer
- Identify supportive care interventions to minimize adverse events with HER2-targeted therapy
- Understand the limitations of health care funding for HER2+ early breast cancer and the need for a risk-adapted strategy
This educational activity is supported by a grant from Puma Biotechnology.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Dr Brahmer has disclosed that she has received consulting fees from Bristol-Myers Squibb (uncompensated), Celgene, Lilly, and Merck. She has performed contracted research for Bristol-Myers Squibb, MedImmune/Astrazeneca, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Chaft has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs referenced in her presentation.
Dr Santini has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Tarhini has disclosed that he has performed contracted research for Incyte and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Elizabeth Cameron, PhD (clinical content planner/reviewer) – no relevant financial relationships
- Christi Gray (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.